OPKO Health (NASDAQ:OPK – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07), FiscalAI reports. The company had revenue of $130.83 million for the quarter, compared to the consensus estimate of $136.62 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The firm’s quarterly revenue was down 56.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 EPS.
Here are the key takeaways from OPKO Health’s conference call:
- OPKO agreed to sell substantially all of BioReference’s remaining operations to Labcorp for about $722 million in cash, with potential 4Kscore royalties of up to $150 million over 10 years. The deal, which remains subject to customary closing conditions, would complete OPKO’s exit from diagnostics and refocus it on biotech and global products.
- Continuing-operations revenue rose 16% to $65.4 million year over year, led by OPKO Iberoamerica, RAYALDEE and mazdutide royalties. Global products reported $6 million of operating income, versus a $1.2 million loss a year earlier.
- Pipeline programs advanced, including completion of enrollment in the planned phase I cohorts for MDX-2301, with management describing its blinded safety profile as favorable. OPKO is preparing subcutaneous dosing studies for several ModeX candidates, while its first in vivo CAR-T program is now targeted for first-in-human studies in mid-2027, later than previously planned.
- Innovative biotech’s operating loss widened to $26.8 million from $22.5 million, as increased research and development activity raised costs. OPKO expects about $125 million in BioReference sale-related costs, and forecast a roughly $40 million loss from discontinued operations in Q4.
- OPKO ended the quarter with $403.2 million in cash, cash equivalents and restricted cash, and repurchased 7.2 million shares for $10.6 million. It withdrew consolidated full-year guidance and issued continuing-operations revenue guidance of $268 million–$278 million; management said it would provide more detail on capital allocation as the Labcorp closing approaches.
OPKO Health Stock Performance
Shares of OPK stock traded up $0.05 during trading on Wednesday, reaching $1.77. 4,819,446 shares of the company’s stock traded hands, compared to its average volume of 5,615,405. The company has a market capitalization of $1.32 billion, a P/E ratio of -19.67 and a beta of 1.52. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. The firm’s 50-day moving average is $1.58 and its 200 day moving average is $1.35. OPKO Health has a 1 year low of $0.98 and a 1 year high of $1.81.
Analyst Upgrades and Downgrades
OPK has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating on shares of OPKO Health in a report on Friday, October 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th. Piper Sandler reissued an “overweight” rating and set a $4.00 target price (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Zacks Research upgraded shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, UBS Group set a $4.00 price target on shares of OPKO Health in a report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, OPKO Health has a consensus rating of “Moderate Buy” and a consensus target price of $3.42.
Read Our Latest Research Report on OPK
OPKO Health Company Profile
OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.
In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.
Read More
- Five stocks we like better than OPKO Health
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
